Pages

Thursday, July 31, 2014

UPDATE: Four doctors arrested in clinic raids | 2014-07-25 | Indianapolis Business Journal | IBJ.com

UPDATE: Four doctors arrested in clinic raids | 2014-07-25 | Indianapolis Business Journal | IBJ.com

Criminal Investigations May 7, 2014: Physician/Owner and Office Manager of McLean Skin Care Clinic Convicted at Trial

Criminal Investigations May 7, 2014: Physician/Owner and Office Manager of McLean Skin Care Clinic Convicted at Trial

Criminal Investigations June 6, 2014: Supplier of Non-FDA Approved Chemotherapy and Cosmetic Drugs Sentenced to 15 Months

Criminal Investigations June 6, 2014: Supplier of Non-FDA Approved Chemotherapy and Cosmetic Drugs Sentenced to 15 Months

Criminal Investigations July 18, 2014: Owner of McLean MedSpa Sentenced for Illegally Importing Non-FDA-Approved Drugs and Using on Patients

Criminal Investigations July 18, 2014: Owner of McLean MedSpa Sentenced for Illegally Importing Non-FDA-Approved Drugs and Using on Patients

Agents raid metro pharmacies, find fake prescriptions for...

Agents raid metro pharmacies, find fake prescriptions for...

Veterianary Sales Representative Jobs Seem to be in Abundance



Eli Lilly and Company - Tulsa, OK
Provides a key leadership role for distributor representatives within their assigned geography Responsible for product placement with targeted accounts in assigned geographical area Responsible...
07/25/2014


Dallas, TX
Veterinary Sales Representative Dallas, TX Our client is hiring a Veterinary Sales Representative for their Dallas, TX territory to generate sales by calling on existing customers, sales leads and...
07/16/2014


Seattle, WA
Veterinary Sales Representative Seattle, WA Our client is hiring a Veterinary Sales Representative for their Seattle, WA territory to generate sales by calling on existing customers, sales leads...
07/16/2014


SWL Recruiting - Richmond, VA
Specialty Sales Representative- Animal Health Our client isa leader inClinicalproducts andservices that are marketed to the Animal Health Market. They have asked us to locate a Sales...
07/15/2014


SWL Recruiting - Oklahoma City, OK
Specialty Sales Representative- Animal Health Our client isa leader inClinicalproducts andservices that are marketed to the Animal Health Market. They have asked us to locate a Sales...
07/15/2014


Phoenix, AZ
Our client is hiring Veterinary Sales Representatives in multiple regions across the United States to generate sales by calling on existing customers, sales leads and potential animal health or...
07/11/2014

HCCA September Health Care Privacy Basic Compliance Academy September 8-11, 2014

September Health Care Privacy Basic Compliance Academy
 
September 8-11, 2014
   San Francisco, CA
 
 
HCCA's Health Care Privacy Basic Compliance Academy is a three-and-a-half-day intensive training program focusing on subject areas at the heart of health care privacy compliance practice. Its faculty is made up of experts in the field. Courses are designed for participants who have a basic knowledge of compliance concepts and some professional experience in a compliance function. Attendees gain comprehensive knowledge of the following:
 
  • Policies, Procedures and Infrastructure
  • Corporate Responsibility
  • Risk assessment
  • Education and Training
  • Routine Auditing and Monitoring
  • Stark and Anti-Kickback
  • HIPAA Privacy and Security
  • Conflict of Interest
 
The Academy addresses methods for implementing and managing compliance programs based on the Seven Element Approach. Courses cover subject matter in each of these areas and better prepare interested parties for the CHPC exam.


Registration Fees

Member Registration  $2500.00
Non-Member Registration  $3000.00

Janis Anfossi JD,CHC% - Assoc Vice President, Rush University Medical Center - Chicago, IL
Brian D Annulis CHC,JD,MHA - Partner, Meade Roach & Annulis, LLP - Chicago, IL
Dwight Claustre CHC-F, CHRC CHRC, CHC-F - Director, AEGIS Compliance & Ethics Center, LLP - Sun City West, AZ
Darrell W Contreras CHC-F,CHPC,CHRC,Esq. - Partner, PlusDelta Technologies, LLC - Lakeland, FL
John C Falcetano CCEP-F,CCEP-I,CHC-F,CHPC,CHRC,CIA CICA - Chief Audit & Compliance Officer, Vidant Health - Greenville, NC
Gregory V Kerr CHC,CHPC MJ - Director of HIPAA Compliance, - Fort Myers , FL
David B Nelson CIPP CISSP, CIPP/G, CIPP/US - Privacy Consultant, - Sacramento, CA
Joan M Podleski CHPC,CHRC,CCEP - Compliance Professional, - Durham, NC
R. Brett Short - Chief Compliance Officer, UK HealthCare / University of Kentucky - Lexington, KY
Debbie Troklus CCEP-F,CCEP-I,CHC-F,CHPC,CHRC - Managing Director, Meade Roach & Annulis, LLP - Louisville, KY

Location Information



Sheraton Fisherman's Wharf Hotel
2500 Mason Street,
San Francisco, CA 94133
(415) 362-5500
 
The HCCA group rate is $209 single occupancy (additional person $20), plus applicable tax(es). This rate is good through August 8 or when the group room block is full, whichever comes first. To makes reservations, please call 1-888-627-7024 and as for the HCCA Privacy Compliance Academy group rate. $35 per day parking is available for attendees.
 
 

CHPC Certification
Be recognized for your experience and knowledge in health care privacy compliance. Take advantage of the opportunity to sit for an optional CHPC exam on the last day of the conference. The CHPC exam requires advance registration and payment separate from the conference registration. To qualify to sit for the CHPC exam, 20 CCB CEUs and the necessary work experience are required. For more information on the CHPC requirements click here.
 
 
To register to sit for the exam please submit the printable application to CCB byFax: 952.988.0146
Mail: 6500 Barrie Rd. Ste 250, Minneapolis, MN 55435Email: ccb @ compliancecertification.org
 


Obtaining CEUs
To obtain CEUs for this conference, fill out the CEU Application given on-site at the conference, noting all sessions attended. Please contact us with questions +1.952.988.0141 or ccb@compliancecertification.org. Note that all credits will be awarded based on actual time on-site spent in session.
 
Approved Credit Types
CCB is in the process of applying for continuing education units. If you have questions, or if you do not see information on your specific accreditation, please contact CCB at
ccb@compliancecertification.org or 888.580.8373.
 
AAPC: 
This program has the prior approval of AAPC for 24 continuing education hours. Granting of prior approval in no way constitutes endorsement by AAPC of the program content or the program sponsor.
 
ACHE: The Health Care Compliance Association is authorized to award 24 hours of pre-approved ACHE Qualified Education credit (non-ACHE) for this program toward advancement, or recertification in the American College of Healthcare Executives. Participants in this program wishing to have the continuing education hours applied toward ACHCE Qualified Education credit should indicate their attendance when submitting application to the American College of Healthcare Executives for advancement or recertification.
 
AHIMA: This program has been approved for 24 continuing education unit(s) for use in fulfilling the continuing education requirements of the American Health Information Management Association (AHIMA). Granting prior approval from AHIMA does not constitute endorsement of the program content or its program sponsor.
 
Compliance Certification Board (CCB): Certified in Healthcare Compliance (CHC), Certified in Healthcare Compliance-Fellow (CHC-F), Certified in Healthcare Privacy Compliance (CHPC), Certified in Healthcare Research Compliance (CHRC), Certified Compliance & Ethics Professional (CCEP), Certified Compliance & Ethics Professional-Fellow (CCEP-F), Certified Compliance & Ethics Professional-International (CCEP-I): CCB has awarded a maximum of 28.8 CEUs for these accreditations.
 
CLE: The Health Care Compliance Association/Society of Corporate Compliance and Ethics is a State Bar of California Approved MCLE provider, a Pennsylvania Accredited Provider, a Rhode Island Accredited Provider, and a Texas Accredited Sponsor. An approximate maximum of 24 clock hours of CLE credit will be available to attendees of this conference. All CLE credits will be awarded based on individual attendance.
 
NASBA/CPE: The Health Care Compliance Association is registered with the National Association of State Boards of Accountancy (NASBA) as a sponsor of continuing professional education on the National Registry of CPE sponsors, Sponsor Identification No: 105638. State boards of accountancy have final authority on the acceptance of individual courses for CPE credit and may not accept one-half credits. Complaints regarding registered sponsors may be addressed to the National Registry of CPE Sponsors, 150 Fourth Avenue North, Suite 700, Nashville, TN 37219-2417. Website:www.nasba.org.

SC Department of Labor, Licensing and Regulation-Boar of Pharmacy August 2014 Newsletter

Oregron Board of Pharmacy August 2014 Newsletter

Deaware State Board of Pharmacy Licensing Outsourcing Facilities

Board Licensing Outsourcing Facilities


On June 18, 2014, the Delaware State Board of Pharmacy

unanimously agreed to license “outsourcing pharmacies”

as described under Section 503B of the Federal

Food, Drug, and Cosmetic Act (FD&C Act). On November

27, 2013, the president signed into law the Drug Quality

and Security Act, legislation that contains important

provisions relating to federal and state oversight of compounding

of human drugs. The new legislation creates a

new section 503B in the FD&C Act under which a facility

that compounds sterile drugs can register to become

an “outsourcing facility.” An outsourcing facility can

qualify for exemptions from Food and Drug Administration

(FDA) approval requirements and the requirement to

label products with adequate directions for use, but it still

must comply with current good manufacturing practice

requirements. The registration of pharmacies as outsourcing

facilities will help FDA identify and more effectively

regulate these facilities. FDA intends to continue to partner

with states in the oversight of drug compounding.
quoted from Delaware Board of Pharmacy August 2014 Newsletter


Delaware State Board of Pharmacy August 2014 Newsletter

Alabama Board of Pharmacy August 2014 Newsletter

Main Street Pharmacy Lawsuit Filed by Injured Woman From Compounded Medications

Main Street Pharmacy Lawsuit Filed by Injured Woman

FDA’s final guidance on traditional compounding essentially unchanged

 

FDA announced the availability of its final guidance for traditional compounding, Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act, in the Federal Register on July 2. Reflecting the agency’s thinking on the compounding part of the Drug Quality and Security Act (the compounding and track-and-trace legislation signed into law late last year), the final guidance closely tracks the draft guidance.
APhA had submitted comments February 3 on the draft guidance. APhA’s comments focused on office-use compounding and limits on out-of-state distribution of compounded drug products, including a 5% limit on such drug products and a Memorandum of Understanding (MOU) between FDA and the states.
It appears that pharmacists can expect additional guidance with policy changes on both issues, according to Jillanne Schulte, JD, APhA Director of Regulatory Affairs.
“Essentially, FDA kept the guidance as it was,” Schulte said. “Based on the listening session with FDA last week, it sounds like they’ll be making policy changes in additional guidance (both for office use and the MOU) that has yet to be released.”
The final guidance doesn’t apply to registered outsourcing facilities under section 503B of the Federal Food, Drug, and Cosmetic Act; the agency will issue this guidance separately. Guidance documents are suggestions or recommendations that do not establish legally enforceable responsibilities, according to FDA.
As intended by the Drug Quality and Security Act, FDA’s final guidance noted that traditional compounding under section 503A will continue to be overseen by states, not the agency.

quoted from here

Steroids In East Texas

By Will Johnson
Messenger Reporter 
EAST TEXAS – As the summer winds downs, the excitement levels on the gridiron and on the volleyball courts will begin to ratchet up a notch. For most area seniors, this will be their last shot at athletic glory. A select few will have the opportunity to continue their athletic careers at the collegiate level. Some have already made verbal commitments to take their talents to a university or junior college.
Some are on the proverbial bubble and need a little help. Unfortunately, a few of these area athletes will use any means necessary to secure an opportunity to play college ball and hopefully receive a coveted shot at the big time. This includes wandering down a dark path into the world of steroids.
It is no secret that the Piney Woods of East Texas produces some of the best athletes in the state. Most are completely natural and get by on God-given talent, hard work and dedication to their respective sport. A certain few, however, will choose to try and enhance their athletic prowess with the aid of chemical substances.
The problems associated with steroid usage will be covered in the next article in this series and are often thought to be associated with those already at the collegiate level and/or in the professional sporting world.
While many may believe the problem has not bled into the high school ranks or at least not into the East Texas High School ranks, a Drug Enforcement Agency (DEA) raid in neighboring Cherokee County pulled back the pine curtain and could possibly expose a dirty little secret hidden right next door to Houston and Anderson Counties.
On Thursday of last week, law enforcement agencies raided a residence in the Mixon area of Cherokee County. Mixon is an unincorporated community between Jacksonville and Troup on State Highway 135. The Cherokee County Sheriff’s Office, Department of Public Safety (DPS) narcotics investigators and DEA agents were present at the time of the raid.
During the investigation, the authorities discovered containers of Anadrol (an oral anabolic steroid), Dianabol (an oral anabolic steroid) and Cialis (a sexual dysfunctional drug). In addition, a notebook of recipes and outlines for the manufacture of steroids was found.
Captain John R. Raffield, with the Cherokee County Sheriff’s Office was contacted about the raid and investigation and said the investigation is ongoing. He added the evidence collected at the scene had been sent to a lab for confirmation as to the exact composition of the seized ingredients/chemicals and expressed some surprise as to what the law enforcement agents believed they had uncovered.
“Steroid labs – we have a retired DEA Agent who is one of my investigators. In his 25 year career with the DEA, he said he had only seen three. The majority of the people who were out there (at the raid) from the DPS narcotics and DEA said they had only seen one in their career. It is just not something you commonly run across,” he said.
continue to read here

Veterinarian, Beef Cattle Professional Service - Texas/Oklahoma

Veterinarian, Beef Cattle Professional Service - Texas/Oklahoma: Click the link provided to see the complete job description.

We Stand FIRM: Unintended Consequences of FDA Regulations

We Stand FIRM: Unintended Consequences of FDA Regulations: Eye surgeon Dr. Brian C. Joondeph described a crazy "unintended consequence" of FDA rules designed to "protect" patient...

FDA Increases Drug and Medical Device Imports Refusal Due to Improper Registration

Hampton, Virginia (PRWEB) July 31, 2014
The U.S. Food and Drug Administration (FDA) continues to refuse an increasing number of imports due to non-registered drug and medical device manufacturers and unlisted or unapproved drugs.[1]
FDA requires foreign drug and medical device manufacturers to register with the FDA before exporting products to the United States. At the time of registration, foreign facilities must identify a U.S. agent and list all drugs or devices intended for use in the United States.
"Section 510 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) requires firms that manufacture, prepare, propagate, compound, or process drugs in the U.S. or that are offered for import into the U.S. to register with the FDA. These domestic or foreign firms must at the time of registration, list all drugs manufactured, prepared, propagated, compounded, or processed for commercial distribution in the U.S. Foreign establishments must identify a U.S. agent at the time of their registration."
"It's clear to us that FDA is increasing enforcement on these types of products," said Registrar Corp Vice President David Lennarz. "It is prudent for companies to make sure they comply before starting or continuing to export to the United States."
continue to read here

FDA Outsourcing Facility Published in Federal Register

  1.  
    1. [PDF]
    2. Outsourcing Facility - The Office of the Federal Register

    1. www.ofr.gov/(S(hocfzv1iqvmfloypsyoixqsl))/.../2014-18111_PI.pdf

    4 hours ago - drug compounded by or under the direct supervision of a licensed ... 352(f)(1)) (concerning the labeling of drugs with adequate directions for use) and (2) section ...

FDA takes steps to help ensure the reliability of certain diagnostic tests

Today, the U.S. Food and Drug Administration took important steps to ensure that certain tests used by health care professionals to help diagnose and treat patients provide accurate, consistent and reliable results.
First, the FDA is issuing a final guidance on the development, review and approval or clearance of companion diagnostics, which are tests used to identify patients who will benefit from or be harmed by treatment with a certain drug. Companion diagnostic tests are intended to aid physicians in selecting appropriate therapies for individual patients. These tests are commonly used to detect certain types of gene-based cancers.
Second, consistent with the requirements of the Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA), the agency is notifying Congress of its intention to publish a proposed risk-based oversight framework for laboratory developed tests (LDTs), which are designed, manufactured and used within a single laboratory. They include some genetic tests and tests that are used by health care professionals to guide medical treatment for their patients. The FDA already oversees direct-to-consumer tests regardless of whether they are LDTs or traditional diagnostics.
“Ensuring that doctors and patients have access to safe, accurate and reliable diagnostic tests to help guide treatment decisions is a priority for the FDA,” said FDA Commissioner Margaret A. Hamburg, M.D. “Inaccurate test results could cause patients to seek unnecessary treatment or delay and sometimes forgo treatment altogether. Today’s action demonstrates the agency’s commitment to personalized medicine, which depends on accurate and reliable tests to get the right treatment to the right patient.”
The companion diagnostics guidance is intended to help companies identify the need for these tests during the earliest stages of drug development and to plan for the development of a drug and a companion test at the same time. The ultimate goal of the final guidance is to stimulate early collaborations that will result in faster access to promising new treatments for patients living with serious and life-threatening diseases. This guidance finalizes and takes into consideration public comment on the draft guidance issued in 2011.
While the FDA has historically exercised enforcement discretion over LDTs (generally not enforced applicable regulatory requirements), today these tests may compete with FDA-approved tests without clinical studies to support their use. The LDT notification to Congress  provides the anticipated details of the draft guidance through which the agency would propose to establish an LDT oversight framework, including pre-market review for higher-risk LDTs, such as those that have the same intended use as FDA-approved or cleared companion diagnostics currently on the market. The draft guidance would also propose to phase in enforcement of pre-market review for other high risk and moderate risk LDTs over time.
The agency intends to propose continuing to exercise enforcement discretion for low-risk LDTs, LDTs for rare diseases and, under certain circumstances, LDTs for which there is no FDA-approved or cleared test.
“With today’s notification of the agency’s intent to issue the lab-developed test draft guidance, the FDA is seeking a better balanced approach for all diagnostics. The agency’s oversight would be based on a test’s level of risk to patients, not on whether it is made by a conventional manufacturer or in a single laboratory, while still providing flexibility to encourage innovation that addresses unmet medical needs,” said Jeffrey Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health.
The FDA also intends to publish a draft guidance outlining how laboratories can notify the FDA that they are currently manufacturing and using LDTs, how to provide information about their LDTs, and how they can comply with the medical device reporting requirements.
A provision in FDASIA requires the FDA to provide at least 60 days’ notice to Congress before the agency publishes for public comment any draft guidance on the regulation of LDTs. As such, the comment period will open at a later date when the draft guidances are published in the Federal Register and the public is alerted to the start of the comment period. The agency also intends to hold a public meeting during the comment period to collect additional input.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
continue to read here

FDA Cell Based Products for Animal Use

CVM Update – FDA Issues Draft Guidance for Industry on Cell-Based Products for Animal Use – http://www.fda.gov/AnimalVeterinary/NewsEvents/CVMUpdates/ucm407376.htm
 
 
Draft Guidance of Industry #218 - Cell-Based Products for Animal Use – http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM405679.pdf

Animal Food & Feeds Food Safety Modernization Act and Animal Feed

Animal Food & Feeds Food Safety Modernization Act and Animal Feed

CVM Updates FDA Announces FY 2015 Animal Drug User Fee Rates for ADUFA and AGDUFA

CVM Updates FDA Announces FY 2015 Animal Drug User Fee Rates for ADUFA and AGDUFA

Interest surges in Medicare bundled-payment initiative

read here

FDA July 30, 2014 Enforcement Report

Estimates for the non-FDA approved compounded bioidentical hormone therapy combination sales of estradiol and progesterone products sold by compounding pharmacies are approximate $1.5 billion per year and the FDA-approved market approximates $625 million per year.

quoted from here

Form 8-K for THERAPEUTICSMD, INC. --clinical trials for advanced hormone therapy



Form 8-K for THERAPEUTICSMD, INC.



30-Jul-2014Other Events

Item 8.01. Other Events. On July 30, 2014, TherapeuticsMD, Inc., a Nevada corporation, filed a prospectus supplement with the Securities and Exchange Commission under its effective shelf registration statements on Form S-3 (the "Prospectus") pursuant to Rule 424 promulgated under the Securities Act of 1933, as amended (the "Securities Act"). The discussion below contains certain updated disclosures regarding the Company's business included the Prospectus. Unless the context otherwise requires, all references in this Current Report on Form 8-K to "TherapeuticsMD," "TXMD," "Company," "our company," "we," "us," or "our" refer to TherapeuticsMD, Inc., a Nevada corporation, and its subsidiaries, VitaMedMD, LLC, a Delaware limited liability company, or VitaMed, and BocagreenMD, Inc., a Nevada corporation, or BocaGreenMD. vitaMedMD�, TherapeuticsMD�, and BocaGreenMD� are registered trademarks of our company.
Our Company
We are a women's health care product company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal dryness. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins and cosmetics. We have obtained U.S. Food and Drug Administration, or FDA, acceptance of our Investigational New Drug, or IND, applications to conduct clinical trials for four of our hormone therapy drug candidates: TX-001HR, our oral combination of progesterone and estradiol; TX-002HR, our oral progesterone alone; TX-003HR, our oral estradiol alone; and TX-004HR, our vaginal suppository estradiol alone. We are currently conducting phase 3 clinical trials for TX-001HR and TX-002HR; and we currently intend to begin a phase 3 clinical trial for TX-004HR in the third quarter of 2014. We have no current plans to conduct clinical trials for TX-003HR.
continue to read here

Are pharmacies the answer for less-costly pet Rxs?


At least two U.S. senators believe so. They’ve promised to introduce legislation that would require veterinarians to provide written prescriptions so customers can competitively shop for pet medications.
Sens. Charles Schumer (D-NY) and Richard Blumenthal (D-Conn) said pet owners are paying a 240% markup when they buy drugs from veterinarians.
During a recent press conference in New York City’s Greenwich Village, the senators said a similar law for optometrists significantly lowered the costs of contact lenses.
continue to read here

FDA has approved Targiniq™ ER, an opioid pain reliever designed to be more resistant to abuse. The drug is an extended-release/long-acting (ER/LA) opioid analgesic for treating pain severe enough to require around-the-clock, long-term opioid treatment, and for which alternative treatment options are inadequate.

read here

NABP: Unique Pharmaceuticals Recalls All Sterile Compounded Preparations Due to Lack of Sterility Assurance

read here

NABP: FDA Reiterates Warning Against Using NuVision Pharmacy Products

read here

MedX Pharmacy Relocates to New Facility

The pharmacy announces new changes.

Sugar Land, TX (PRWEB) July 30, 2014

New pharmacy dean looks to school’s future-Compounding Center Being Built

New pharmacy dean looks to school’s future

Wednesday, July 30, 2014

Older FDA Compounding Letter: 2007 Med-South Pharmacy Inc. 28-Sep-07

2007 Med-South Pharmacy Inc. 28-Sep-07

Older FDA Compounding Letter: 2003 Medical Park Pharmacy 25-Nov-03

Older FDA Compounding Letter: 2003 Plum Creek Pharmaceuticals, Inc. 07-Oct-03

Older FDA Compounding Case: 2001 Unique Pharmaceuticals, Ltd. 10-Oct-01

2001 Unique Pharmaceuticals, Ltd. 10-Oct-01

Some of the older FDA Compounding Cases: 2004 The Veterinary Pharmacy, Inc. 06-Aug-04

2004 The Veterinary Pharmacy, Inc. 06-Aug-04

Seventh Question of the Day July 30, 2014 How are so many compounding pharmacies able to afford the state-of-art compounding labs with clean rooms that can cost six to seven figures?


Sixth Question of the Day July 30, 2014 Who were the 18 original Fellows of the International Academy of Compounding Pharmacists and how much money have they made from compounding endeavors?


PCCA to Provide Seminar on Navigating Third-Party Billing for Compounded Medications as part of serve provided by Compounding Pharmacy Management Services (CPMS)

Navigating Third-Party Billing for Compounds


Summary

Compounds are different by their nature. And so are the approaches various third-party insurance companies take in paying them. If you bill third-party insurance, you’re already familiar with the hassles that often arise when trying to process a claim for a compounded prescription. Or maybe you’ve just heard about it and have avoided billing third-party altogether.

That’s where PCCA’s Third-Party Solutions steps in.

As part of a new service provided by Compounding Pharmacy Management Services (CPMS), this one-day workshop will cover the basics of third-party billing, including the ins and outs of version D.0. Then, the team will drill down and show you best practices for processing claims with the top insurance plans – including CVS Caremark, Express Scripts, Medco, and Prime Therapeutics. The team will dive deep into these plans to educate you on exactly what each plan will pay for. Benefit from our expertise so you can spend your valuable time on your most important task – serving patients.

Why should you attend?

  • If you’re already billing third-party insurance, we’ll teach you how to become more efficient, how to reduce audits, what to do when you do get audited and more.
  • Learn best practices for billing, including training using PK Software’s billing programs. Not using PK Software at your pharmacy? No problem – the team will provide information for whatever software you’re using.
  • And more!
Third-Party Solutions is open to all PCCA members, and is run by Gary McCrory, RPh, CCN, a PCCA member store owner with 30 years of experience who understands the challenges of third-party billing from the perspective of you, the independent compounding pharmacist.

Details

  • When

  • Saturday, September 20, 2014
    7:00 AM - 5:00 PM
    Central Time
                            

  • Where

  • PCCA Learning Center
    9901 South Wilcrest Dr.
    Houston, Texas 77099
    1-800-331-2498

One Quality Standard: OIG Issues Favorable Advisory Opinion on Drug Manu...

One Quality Standard: OIG Issues Favorable Advisory Opinion on Drug Manu...: Source: FDA Law Blog Posted: 29 Jul 2014 08:43 PM PDT By Jay W. Cormier & Alan M. Kirschenbaum – In an advisory opinion posted on ...

ACLU Calls for Death Penalty Moratorium After Botched Executions

 

July 30, 2014
 
read here

List of Pharmacists, Pharmacies, Labs and Organizations That Donated Money to IACP for the Building of its Headquarters

Diamond Sponsor


Thomas and Alice Marks

Platinum Sponsor


Bob Seiwert, Sierra Compounding Pharmacy

Gold Sponsors


Lee and Mary Ann Berrettini

Gallipot

Bob and Diana Harshbarger

Health Care Logistics

Gary and Vicki Holst

International Journal of Pharmaceutical

Compounding

Marty Jones and Pat Baloga

Medaus on behalf of Steven Russell

Ray and Alfred Moreno, Universal Arts

Compounding Pharmacy of South Florida

in Honor and Praise of our loving

parents, Maximino and Maria Moreno

John D. and Caroline Musil and Family

David and Diane Nicoletti

PCCA

Sherry Ross

Bob and Janie Scarbrough

Spectrum Pharmacy Products

Eric Vidrine, Professional Arts Pharmacy

David Zava and ZRT Labs

Silver Sponsors


Analytical Research Laboratories

Bill Burch and Jennifer Burch

Pat and Jan Downing, Jenny Yoakum,

Dee Downing and Jana Downing

Eric Everett and Lisa Everett

Brian Fichter, VitaMaxRx, Inc.

Paul Franck

Dan and Laura Fucarino

Phil Hagerman, Diplomat Specialty

Eric and Carolyn Holgate

IACP Staff

Scott Karolchyk and Bernie Covalesky

Mike Leake

Terry and Greg Mielke, Thrifty Health

and Compounding

Donna Patterson, The Apothecary

Robert P. Potts and Associates

Sam and Mary Susan Pratt

John Preckshot

Kim and Janet Tenreiro

Evelyn Timmons and Steve Timmons

E. Pat Vann, Vann Healthcare Services

Gary Wilburn

Bronze Sponsors


Hank Abbott, Birds Hill Pharmacy

Eldon Armstrong, Hawthorne Pharmacy

Leo and Beverly Blais

Carie Boyd

Ben Briggs

Richard Brisson

Al Brown and Liberty Drug

James Buderer and Matthew Buderer,

Buderer Drug Co.

Steven Charles

Compounding Shop, Inc.

John and Alice M. DeMars

Gina Ford

Peter and Anne Marie Ford

Henry Gialanella

Jim Gillespie

Dana Gordon, CAPRx

Gene and Caren Gresh

John Herr and Robert Zadra

Hoagland Pharmacy

Dick Holm

Sue Horton and Central Iowa Compounding

Bob and Kathy Hoye

Bill and Barbara Johns

Raymond and Kathleen Knepp

Matthew H. and Jayne Kopacki

Mark Mandel and Nick Flocco

Mike and Keryn McMahan

Medisca

Rich and Kelly Moon, Southern Tier

Home Infusion

Moore’s Pharmacy, Inc.

Pine Pharmacy

North Dakota Compounders

Mike Pass

Scott and Amy Popyk, Health

Dimensions, Inc.

Wade and Jennifer Siefert

Marshall Tobin

William and Jonette Wills, Grandpa’s

Compounding Pharmacy

Joe Wise and Wise Pharmacy

Robert Wood and Anthony Buchta,

Central Ohio Compounding

Gene and Cheryl Zale

Mortar and Pestle Sponsors


Harvey and Carol Ahl

Patsy Angelle

Aquidneck Pharmacy and Wellness

Claude Banks

Jeff Barris, Pacifica Pharmacy

Jerry and Jean Beamer

Barry and Grace Bilbro

Eugene Bockrath

Douglas and Jennifer Boudreaux

Burman’s Pharmacy

Gene Carlson and Schott’s Pharmacy

Randy and Susan Caudle

Karl Clearwaters, Herbst Apothecary

David and Debbie Creecy, Poquoson

Pharmacy

Dr. Dan Daniel

Gerald and Cheryl DuFresne

Kim and Patricia Fulmer

Gary and Ruth Glisson

Henry and Myra Herring

Jeff Hill, Hill’s Compounding Pharmacy

Jeff and Angela Jackson

Kathy and Pat Jackson

Patty Johnston and Larry Frail,

Colony Drug

Dean and Linda King

L.D. King

Kubat Pharmacy

Deril and Robbin Lees

Leiter’s Pharmacy

Bill and Lise Letendre

David Liebman

Joe Lorello

Dick and Amelda McCortney

Randy and Paula Mentzer

Svet Milic

Bill and Jan Mixon

Lee and Jaclyn Ori

Jim and Amy Paoletti

Dean and Terri Parker

James Perry

Ron Petrin

Martin and Rosemary Pietruszewski

Rudy and Carole Prinz

Dana Reed-Kane and Tom Reed,

Reed’s Compounding

Jerrod and Drenda Roberts

Shara and Mike Rudner/George and

Barbara Grumet

Tony and Sandra Sabutis

Ari Schafer

Larry and Linda Shelton

Lee and Kerri Shinabery

Scott Snyder

David Stahlberger, Matthew H. and

Jayne Kopacki, Pompton Pharmacy

Mike and Debra Stein

Storey Marketing

Irv Swartz

Pat and Theresa Travis, CLEANAIR

David and Terry Vasenden

John and Tara Voliva

Scott and Gretchen Watts

Don and Karen West

Irene White and Dennis Slack

Gary and Brenda Wingate

Terry Wingo

Bill and Gloria Winkowski

Dana and Annette Woods

Patron Sponsors

Vern Allen, Premier Pharmacy Labs, Inc.

Jay and Lisa Ashworth

Nick Birkel, Pharmacy Specialty Services

Janice Bopp and Mar-Main Pharmacy

Janet Carter, Prescription Alternatives

Custom Dosing Pharmacy

Lizzie Dragon

Larry and Lezlie Durrant

Kevin and Beth Evetts

Glen Hadaway

Henry T. Hayden, Hayden Drug

Pete Hueseman, Bellevue Pharmacy

Solutions

Lorraine Kaup and Kaup Pharmacy

Craig and Sally Kvam

George and Barbara Muller

Andy Naglak

Neal and Ro Pease

Richard and Diantha Rochefort

Joe Rossetti

Scott Robinson’s Prescriptions/Bruce

Winkelman

John and Waynie Stephenson

Scott Wepfer

Susanne Williams

Individual Sponsors

Ray and Mary Sue Adams

Mel Alter

Kevin and Amy Atkins

Ball Ground Pharmacy

Ronnie Baggett

Janet Beard

Verne and Colleen Betlach

Bruce Biundo

Michael Blaire, Diamondback Drugs

Diane Boomsma and Merv Sands

Bill Chaney

Michael and Carol Collins

Charles Daleo

David and Nancy DeMartini

Dickson Apothecary

Disco Rex Pharmacy

Don Fellows

Ken Fitzgerald

W. Benjamin Fry

Robert Geldreich

Jennifer Goodrum

John and Joe Grasela, University

Compounding Pharmacy

Dale Harrison and Dr. Laurie Ellen

Spence

Mike and Marcia Haulsee

Rayeane and Bentley Hawley

Bruce A. Hinkle

Tom and Dot Hornsby

Ken and Nancy Hughes

Michael Hunter

Alan, Beverly and Adam Israel

Fred Kinnard, Kinnard’s Pharmacy

James Krasnow

Yvette Ladd, Halls Pharmacy

Eddie Tom Lakey

Jung and Marilynn Lee

A. Blair Lundberg

Larry Mayhew

Joe McCloskey

Linda F. McElhiney

Angie Meeker

Sammi Molvi, Health Solutions Pharmacy

Gary Newton

Patricia Paget

Roger Pennington, Westlab Pharmacy

Portage Pharmacy

Jeff and Stacy Robins

Rx South

Jade and Brenna Schuckman

Jim Schwartz, King Pharmacy #2

Kelly and Nancy Selby

Linn and Barbara Shaffer

Jeffrey B. Sherr, Apple Discount Drugs

Chris and Patti Simmons

Stephen F. Skinner, Specialty Pharmacy

Charles and Alleene Smith

In Honor of Kay Sparks

Jack and Carol Stafford

Gerald Stone, The Drug Shop

Angie Svoboda, Good Life Health Services

Bill Swail, Peoples Pharmacy

Tom Switzler

Tom and Tami Talbert, in Honor of

Kay Sparks

Tar Heel Drug

Dr. Eldred Taylor

Union Square Pharmacy

Cathy and Ron Windish

Steve Zaver

quoted from here